aficamten investigational

Selected indexed studies

• A plain language summary of the SEQUOIA-HCM study: aficamten for symptomatic obstructive hypertrophic cardiomyopathy. (Future Cardiol, 2025) [PMID:40415702]
• Emerging treatments in hypertrophic cardiomyopathy: a focus on cardiac myosin inhibitors. (Expert Opin Pharmacother, 2026) [PMID:41940719]

_Worker-drafted node — pending editorial review._